Dear Editor,Metabolically induced cancer heterogeneity creates a large source of novel potential targets towards an enhanced therapeutic window alone and in combination with classic chemo-and radiotherapy[1,2].This is...Dear Editor,Metabolically induced cancer heterogeneity creates a large source of novel potential targets towards an enhanced therapeutic window alone and in combination with classic chemo-and radiotherapy[1,2].This is of particular interest for non-small cell lung cancer(NSCLC),which accounts for more than 80%of all lung tumor types characterized by limited responses to current treatment options[3–5].展开更多
基金supported by the Swiss National Science Foundation,Switzerland(grant 320030_176088 to Johannes Häberle)the Wolfermann-Nägeli-Stiftung,Switzerland(grant 2020/28 to Martin Pruschy).+2 种基金supported by the Research Council of Norway(NOR-OPENSCREEN 245922/F50)supported by The Fundación Ramón Areces(grant CIVP20A6610)supported by a grant from European Union’s Framework Program for Research and Innovation Horizon 2020(2014-2020)under Marie Skłodowska-Curie(Grant Agreements No.860245)(ITN THERADNET)to Marvin Kreuzer and Martin Pruschy.
文摘Dear Editor,Metabolically induced cancer heterogeneity creates a large source of novel potential targets towards an enhanced therapeutic window alone and in combination with classic chemo-and radiotherapy[1,2].This is of particular interest for non-small cell lung cancer(NSCLC),which accounts for more than 80%of all lung tumor types characterized by limited responses to current treatment options[3–5].
